Clinical trials: Severe Alcohol Use Disorder
Major Depressive Disorder, Alcohol Use Disorder
Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.
Mirtazapine is a non-SSRI (selective serotonin reuptake inhibitor) medication with a unique structure and mechanism of action. Recent study results suggest that mirtazapine may be more effective and faster acting than other…
- Trial name
- PT-MAD (NCT02185131)
- Testing
- Mirtazapine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Pittsburgh
Alcohol Abuse, Alcohol Use Disorder
The Effect of Comorbid Alcohol/Substance Use
Study Design This study was designed as a comparative, cross-sectional case-control study examining the effect of comorbid alcohol and substance use disorder (ASUD) on clinical course and social inclusion among individuals with…
- Conditions
- Alcohol Abuse, Alcohol Use Disorder, Substance Use Disorders, Severe Mental Disorder
- Trial name
- NCT07692984
- Testing
- case (comorbid diagnosis), control
- Where
- Turkey (Türkiye)
- Volunteers
- 297 people
- Sponsor
- Abant Izzet Baysal University
Alcohol Use Disorder
Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder
This study aims to determine the safety and preliminary efficacy of psilocybin-assisted psychotherapy in improving alcohol-related outcomes among adults with severe alcohol use disorder in a a double-blind, dose-comparison…
- Trial name
- NCT07296094
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Brigham and Women's Hospital
Alcohol Use Disorder
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks.
- Trial name
- RENEW-ALC-1 (NCT07219966)
- Testing
- LY3537031
- Where
- 117 sites in United States, Belgium and 6 more
- Volunteers
- 1,100 people
- Sponsor
- Eli Lilly and Company
Alcohol Use Disorder
Severe Alcohol-use Disorder: a tDCS and Response Inhibition Training Intervention
Most severe forms of alcohol-use disorder are thought to reflect an abnormal interplay between two neural systems: an overly active impulsive one driven by immediate rewards prospects and a weak reflective one, tuned on long-term…
- Trial name
- ALCOSTIM (NCT03447054)
- Testing
- Combined TDCS active and ICT active, Combined TDCS active and ICT inactive
- Where
- Belgium
- Volunteers
- 136 people
- Sponsor
- Brugmann University Hospital
Alcohol Use Disorder, Alcoholic Hepatitis
Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH
Given the severe consequences of alcohol relapse following liver transplantation for alcoholic hepatitis (AH-LT), it is critical to accurately identify alcohol use and implement alcohol interventions early in the post-transplant…
- Trial name
- NCT03845205
- Testing
- Integrated AUD Treatment
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University
Major Depressive Disorder, Alcohol Use Disorder
Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression.
The purpose of this study is to look at the safety of a study treatment with stem cells in Alcohol Use Disorder And Major Depression (AUD-MD) subjects.
- Trial name
- Alaunus (NCT03265808)
- Testing
- allogeneic human mesenchymal stem cells (allo-hMSCs)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Ihsan M Salloum, MD, MPH
Alcoholic Hepatitis
Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32)
This study is designed to evaluate the hypothesis that patients with severe acute alcoholic hepatitis have lower morbi-mortality if the patients receive treatment with corticosteroids + NAC, compared to patients that only receive…
- Trial name
- NCT05294744
- Testing
- N-acetylcysteine
- Where
- Spain
- Volunteers
- 390 people
- Sponsor
- Bioaraba Health Research Institute
Substance Abuse, Substance Dependence
Group Therapy for Women Prisoners With Comorbid Substance Use and Depression
The purpose of the study is to determine whether interpersonal psychotherapy is effective for treating co-occurring depression and substance use among women prisoners.
- Conditions
- Substance Abuse, Substance Dependence, Depressive Disorder
- Trial name
- NCT00606996
- Testing
- Group interpersonal psychotherapy (IPT-G), Psychoeducation on co-occurring disorders (PSYCHOED)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Brown University
Major Depressive Disorder, Alcohol Use Disorder
Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder
To evaluate if naltrexone plus ketamine is effective in reducing depression and alcohol consumption.
- Trial name
- NCT03658330
- Testing
- Ketamine + Naltrexone
- Volunteers
- 5 people
- Sponsor
- VA Connecticut Healthcare System
Addiction, Alcohol
Impact of a Brief Motivational Intervention Including Counter-marketing Arguments With a Population of Patients With Moderate to Severe Alcohol Use Disorders Who Are Followed up on an Outpatient Basis (Primary Care or Addictology) (DEPREV_Phase 3)
Alcohol consumption is the second cause of avoidable death after tobacco. The Evin law was constructed in 1991 with the aim of reducing exposure to alcohol marketing among the youngest.
- Trial name
- NCT04881500
- Testing
- Motivational interview, Routine Care
- Where
- 6 sites in France
- Volunteers
- 83 people
- Sponsor
- University Hospital, Brest
Major Depressive Disorder, Alcohol Use Disorder
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder
The purpose of this study is to determine whether psilocybin, a hallucinogenic drug, is effective in reducing depressive symptoms and amount of drinking in patients with co-occurring Major Depressive Disorder (MDD) and Alcohol…
- Trial name
- PsiloMDDAUD (NCT04620759)
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Johns Hopkins University
Depressive Disorder, Major, Alcoholism
Vortioxetine for Treatment of Depressive Mood and Alcohol Use
This is a randomized, double-blinded, placebo-controlled, multicenter study. A total of 128 subjects will be randomly assigned to a test group or placebo group in a 1:1 ratio.
- Trial name
- NCT04498897
- Testing
- Vortioxetine, Acamprosate
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- Hanyang University Seoul Hospital
OCD, Major Depressive Disorder (MDD)
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics
This is an observational study which does NOT directly administer a psychedelic substance but rather recruits participants who are already participating in another clinical trial in which they may receive a serotonergic…
- Conditions
- OCD, Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD), Healthy Volunteer
- Trial name
- NCT06624137
- Testing
- Serotonergic Psychedelic
- Where
- 2 sites in United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Yale University
Alcohol Dependence, Major Depression
Acamprosate in Alcoholics With Comorbid Anxiety or Depression
STUDY OBJECTIVES: The primary objective of this study is to compare the safety and efficacy of acamprosate versus placebo in the treatment of alcohol dependence in adults with co-occurring mood or anxiety disorders (specifically…
- Conditions
- Alcohol Dependence, Major Depression, Social Anxiety Disorder, Generalized Anxiety Disorder
- Trial name
- NCT00330174
- Testing
- Acamprosate
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- Medical University of South Carolina
Alcohol Use Disorder, Severe
Impact of Omega 3 in Alcohol Use Disorder
The goal of this clinical trial is to investigate the biological pathways underlying the beneficial effect of omega-3 polyunsaturated fatty acids (n-3 PUFA) on mental health in patients with alcohol use disorder.
- Trial name
- W3-AUD (NCT05899660)
- Testing
- Active Comparator: Omega-3
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Université Catholique de Louvain
Severe Alcohol Use Disorder
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority Trial
- Trial name
- NCT06160232
- Testing
- Psilocybin (high dose)
- Where
- Belgium
- Volunteers
- 62 people
- Sponsor
- Brugmann University Hospital
Severe Alcoholic Hepatitis
Rifaximin Use in Severe Alcoholic Hepatitis
This study aimed to investigate the effect of decontamination by rifaximin in severe alcoholic hepatitis patients. Patients who take corticosteroid or pentoxifylline will be randomly allocated to rifaximin group or control group.
- Trial name
- NCT02485106
- Testing
- Rifaximin, Corticosteroid or pentoxifylline
- Volunteers
- 170 people
- Sponsor
- Saint Vincent's Hospital, Korea
Disease, Mental Disorders, Severe
Multifamily Group Psychoeducation for SUD's in Turkey
The aim of this study is to investigate the effects of multi-family group psychoeducation (MFGP) on the families of people living with a diagnosis of substance abuse disorder on patients and their families.
- Conditions
- Disease, Mental Disorders, Severe, Substance-Related Disorders, Substance Use Disorders
- Trial name
- NCT05564559
- Testing
- multifamily group psychoeducation
- Where
- Turkey (Türkiye)
- Volunteers
- 35 people
- Sponsor
- Ege University
Major Depressive Disorder, Alcohol Use Disorder
Cognitive Dysfunction in the Addictions Study - Project 4 (P4)
The prefrontal cortex, although well established as an efficacious target for the treatment of major depressive disorder (MDD), has recently come into favour as a therapeutic target for alcohol use disorders (AUD).
- Trial name
- CDiA-P4 (NCT06299787)
- Testing
- intermittent theta burst stimulation
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Centre for Addiction and Mental Health